MAbSilico
MAbSilico is a TechBio company specializing in AI-based solutions for antibody drug design and discovery. Founded by a multidisciplinary team of scientists, the company leverages computational methods to accelerate the discovery process, providing fully characterized, high-affinity antibodies in just 21 days. MAbSilico's innovative approach combines computational science, biology, and software development, allowing clients in biotech and pharma to reduce risks and costs associated with antibody development. With over 55 customers globally and ongoing partnerships, MAbSilico is positioned to transform the landscape of therapeutic antibody discovery.
MAbSilico
MAbSilico is a TechBio company specializing in AI-based solutions for antibody drug design and discovery. Founded by a multidisciplinary team of scientists, the company leverages computational methods to accelerate the discovery process, providing fully characterized, high-affinity antibodies in just 21 days. MAbSilico's innovative approach combines computational science, biology, and software development, allowing clients in biotech and pharma to reduce risks and costs associated with antibody development. With over 55 customers globally and ongoing partnerships, MAbSilico is positioned to transform the landscape of therapeutic antibody discovery.